O

Orion Oyj
OMXH:ORNBV

Watchlist Manager
Orion Oyj
OMXH:ORNBV
Watchlist
Price: 42.44 EUR -0.79% Market Closed
Market Cap: 6B EUR
Have any thoughts about
Orion Oyj?
Write Note

Relative Value

The Relative Value of one ORNBV stock under the Base Case scenario is 62.05 EUR. Compared to the current market price of 42.44 EUR, Orion Oyj is Undervalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORNBV Relative Value
Base Case
62.05 EUR
Undervaluation 32%
Relative Value
Price
O
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
20
vs Industry
28
Median 3Y
4.6
Median 5Y
4.6
Industry
2.5
Forward
3.9
vs History
19
vs Industry
19
Median 3Y
25.4
Median 5Y
23.7
Industry
21.8
Forward
18.5
vs History
19
vs Industry
18
Median 3Y
24.8
Median 5Y
19
Industry
16.1
vs History
33
vs Industry
12
Median 3Y
28.1
Median 5Y
26.2
Industry
23.8
vs History
7
vs Industry
9
Median 3Y
7.2
Median 5Y
6.8
Industry
2.1
vs History
15
vs Industry
26
Median 3Y
4.7
Median 5Y
4.5
Industry
2.7
Forward
3.9
vs History
12
vs Industry
25
Median 3Y
8.1
Median 5Y
7.7
Industry
5.2
vs History
15
vs Industry
18
Median 3Y
19.3
Median 5Y
17.6
Industry
13.5
Forward
12.8
vs History
22
vs Industry
21
Median 3Y
20.4
Median 5Y
18.5
Industry
16.8
Forward
14.9
vs History
19
vs Industry
19
Median 3Y
24.2
Median 5Y
18.6
Industry
15.2
vs History
14
vs Industry
11
Median 3Y
37.4
Median 5Y
21.8
Industry
19.3
vs History
73
vs Industry
18
Median 3Y
5.3
Median 5Y
5.5
Industry
1.9

Multiples Across Competitors

ORNBV Competitors Multiples
Orion Oyj Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FI
Orion Oyj
OMXH:ORNBV
6B EUR 4.7 25.7 20.5 20.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
755.8B USD 18.5 90.3 48.5 54.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 4 23.9 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
251.8B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
FI
O
Orion Oyj
OMXH:ORNBV
Average P/S: 382 942.4
4.7
57%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
FI
O
Orion Oyj
OMXH:ORNBV
Average P/E: 31.7
25.7
98%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FI
O
Orion Oyj
OMXH:ORNBV
Average EV/EBITDA: 415.7
20.5
121%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FI
O
Orion Oyj
OMXH:ORNBV
Average EV/EBIT: 1 812.2
20.5
153%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.1
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top